The latest edition of our "From the Bench" series examines creative research approaches presented at the AACR Annual Meeting 2026 enabling new insights into cancer.
An AACR grant to study menin's structure gave researchers the 3D map they needed to produce new treatments for acute myeloid leukemia.
In April 2026, AACR's journals editors highlighted studies on cancer survivors taking GLP-1 agonists, an immunotherapy-boosting bacteria, and more.
Injecting immunotherapy directly into precancerous oral lesions may be an effective way to prevent progression to cancer without surgery.
People with alveolar soft part sarcoma can receive immunotherapy treatment for an extended period without long-term side effects.
Nicotine-based e-cigarettes likely increase risk for oral and lung cancers, and adjusting radiation after chemotherapy preserves low breast cancer recurrence rates.
In March, AACR's journals editors highlighted studies on the development of pediatric leukemia, the use of low-dose tamoxifen, and more.
Elizabeth M. Jaffee and Philip D. Greenberg opened AACR IO 2026 with a look at cancer vaccines and the next generation of engineered T cells.
Colorectal cancer cases are becoming more common in younger adults, but there are now more options for screening beyond colonoscopies.
Researchers and a patient advocate weighed in on current and emerging treatment options for each stage of triple-negative breast cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More